Form 4: Phathom Pharmaceuticals CFO Molly Henderson Reports Acquisition of 7,500 Shares of Common Stock

Molly Henderson, CFO and CBO of Phathom Pharmaceuticals, reports the acquisition of 7,500 shares of common stock and ownership of 102,763 shares.

Summary

• On May 31, 2024, Molly Henderson, CFO and CBO of Phathom Pharmaceuticals, acquired 7,500 shares of common stock.
• These shares were granted as restricted stock units (RSUs) at a price of $0.
• One third of the RSUs will vest on each of the first three anniversaries of December 18, 2023, subject to continued service.
• Each RSU represents a contingent right to receive one share of common stock of Phathom Pharmaceuticals.
• Following the reported transaction, Henderson directly owns 102,763 shares of common stock and indirectly owns 1,911.27 shares through a 401(k).

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive. The grant of RSUs is a standard practice and aligns management's interests with shareholders. There are no immediate negative implications.

Positives

• The grant of RSUs to the CFO and CBO aligns her interests with those of the shareholders.
• The vesting schedule incentivizes continued service and commitment to the company's success.

Industry Context

Form 4 filings are standard practice for reporting changes in beneficial ownership by company insiders, providing transparency to investors.

Comparison to Industry Standards

• Equity compensation in the form of RSUs is a common practice among publicly traded pharmaceutical companies to incentivize and retain key executives.
• Vesting schedules typically range from three to five years, with annual or quarterly vesting intervals, aligning with industry norms.
• Comparable companies such as Biohaven Pharmaceuticals (before its acquisition by Pfizer) and Amgen also utilize RSUs as part of their executive compensation packages.

Stakeholder Impact

• Shareholders may view the RSU grant as a positive sign, aligning management's interests with the company's long-term success.
• Employees may see this as a positive indicator of the company's commitment to its leadership team.

Key Dates